Biotech M&A – 2019 Deals

Biotech M&A With a Strong Start in 2019: More Deals to Follow?

Date Acquirer Co. Acquirer Ticker Acquired Co. Acquired Ticker Deal value Price/Share CVR (if any) Notes
01/03/2019 Bristol Myers BMY Celgen CELG $74B $102.43
$50 +1 BMY share
CVR $9.00 upon FDA approval of all 3 of ozanimod
01/07/2019 Eli Lilly LLY Loxo Oncology LOXO $8B $235
02/1/2019 Merck MRK Immune Design IMDZ $300M $5.85 Was $1.42 >300% Premium
02/25/2019 Roche RHHBY Spark Therapeutics ONCE $4.8B $114.50
02/25/2019 Ipsen IPSEY Clementia Pharmaceuticals CMTA $1.04B $25 CVR $6.00 upon FDA acceptance of the NDA filing (+$263M)
02/27/2019 Sarepta SRPT Myonexus Private $165M
03/04/2019 Biogen BIIB Nightstar NITE $877M $25.50
03/12/2019 Smith & Nephew SNN Osiris Therapeutics OSIR $660.5M $19
04/12/2019 Merck KGaA MRK Versum Materials VSM $6.6B $53
05/08/2019 Pfizer PFE Therachon Holding Private $340M upfront $470M Milestones
05/08/2019 Novartis NVS Xiidra from Takeda Xiidra eye drug $5.3B
05/21/2019 Merck MRK Peloton Therapeutics PLTX $1.05B Just before IPO $1.15B milestones
06/10/2019 Merck MRK Tilos Therapeutics Private $773M
06/17/2019 Pfizer PFE Array ARRY $11.4B $48
06/25/2019 AbbVie ABBV AGN Allergan $63B 0.8660 ABBV share and $120.30/ Cash

 

For M&A 2018 full table click here https://www.chimeraresearchgroup.com/biotech-ma-2018-deals/